Literature DB >> 1302044

Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1.

L Gu1, F J Gonzalez, W Kalow, B K Tang.   

Abstract

Six human cytochrome P450s expressed in HepG2 cells using vaccinia virus cDNA-directed expression, were used to study the biotransformation of caffeine and its metabolites. CYP1A2 alone was responsible for caffeine 3-demethylation and paraxanthine 7-demethylation; in addition, 1A2 catalysed virtually all reactions related to caffeine and its metabolites. The metabolic profile of caffeine biotransformation by CYP1A2 averaged 81.5% for paraxanthine, 10.8% for theobromine and 5.4% for theophylline formation. It remained quite uniform when caffeine concentrations were varied. The most striking finding was that CYP2E1 (the ethanol-inducible form) had major influences upon caffeine metabolism: in particular, it catalysed the formation of theophylline and theobromine from caffeine. Thus, the in vivo metabolite profiling of caffeine may reveal CYP2E1 activities in addition to the previously documented activities of CYP1A2, polymorphic N-acetyltransferase and xanthine oxidase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1302044     DOI: 10.1097/00008571-199204000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  61 in total

1.  Determination of -3858G-->A and -164C-->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G-->A mutation between Caucasians and Asians.

Authors:  Liliane Todesco; Michael Török; Stephan Krähenbühl; Markus Wenk
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

2.  PharmGKB summary: caffeine pathway.

Authors:  Caroline F Thorn; Eleni Aklillu; Ellen M McDonagh; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-05       Impact factor: 2.089

3.  Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.

Authors:  R A Popat; S K Van Den Eeden; C M Tanner; F Kamel; D M Umbach; K Marder; R Mayeux; B Ritz; G W Ross; H Petrovitch; B Topol; V McGuire; S Costello; A D Manthripragada; A Southwick; R M Myers; L M Nelson
Journal:  Eur J Neurol       Date:  2011-01-31       Impact factor: 6.089

Review 4.  Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.

Authors:  Will C McClatchey; Gail B Mahady; Bradley C Bennett; Laura Shiels; Valentina Savo
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

Review 5.  Sex differences in the pharmacokinetics of antidepressants: influence of female sex hormones and oral contraceptives.

Authors:  Valérie A Damoiseaux; Johannes H Proost; Vincent C R Jiawan; Barbro N Melgert
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

Review 6.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

7.  Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; S Krahenbuhl; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

8.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; A U Freiburghaus; F Follath
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

9.  Induction of P-450 in workers exposed to dioxin.

Authors:  W Halperin; W Kalow; M H Sweeney; B K Tang; M Fingerhut; B Timpkins; K Wille
Journal:  Occup Environ Med       Date:  1995-02       Impact factor: 4.402

10.  Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity.

Authors:  L J Notarianni; S E Oliver; P Dobrocky; P N Bennett; B W Silverman
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.